SPTX · Seaport Therapeutics, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-11-02 |
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo ™, showing that GlyphAllo did not impair next-morning driving performance compared to placebo Dosed first patient in Phase 2a trial of GlyphAgo ™ in patients with generalized anxiety disorder (GAD) and sleep |
| 2026-10-28 |
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
BOSTON --(BUSINESS WIRE)--Oct. 28, 2026-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced its participation in the Stifel 2026 Healthcare Conference, |
| 2026-10-09 |
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing Detailed data reinforces previously reported topline results demonstrating that GlyphAgo achieved a |
| 2026-10-07 |
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder In Phase 1, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified |
| 2026-09-14 |
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON --(BUSINESS WIRE)--Sep. 14, 2026-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series |
| 2026-09-09 |
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing Key secondary endpoint also met, showing a single evening dose of 250 mg GlyphAllo did not impair |
| 2026-08-31 |
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON --(BUSINESS WIRE)--Aug. 31, 2026-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the |
| 2026-08-03 |
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Enrollment in Phase 2b BUOY-1 trial of GlyphAllo ™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026 Following positive data from completed Phase 1 proof-of-concept trial of |
| 2026-06-08 |
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demonstrate GlyphAgo TM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing Enrollment in |
| 2026-06-08 |
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed New data demonstrate seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid |
| 2026-06-01 |
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the |
| 2026-05-01 |
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON --(BUSINESS WIRE)--Apr. 30, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public offering of 14,160,000 |
| 2026-04-27 |
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson BOSTON, April 27, 2026 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and |
| 2026-04-02 |
Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use GlyphAgo demonstrated a statistically significant 6.8-fold increase in |
Past events
Source: https://investors.seaporttx.com/